Skip to main content

S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics

If a Substance or Method is not defined in this list, please verify with your Anti-Doping Organization.

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. Erythropoietins (EPO) and agents affecting erythopoiesis, including, but not limited to

1.1 Erythropoietin-Receptor agonists e.g.

  • Darbepoietin (dEPO)
  • Erythropoietins (EPO)
  • EPO based constructs (EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA))
  • EPO-mimetic agents and their constructs, e.g. CNTO-530, peginesatide;

1.2 Hypoxia-inducible factor (HIF) activating agents, e.g.

  • Cobalt
  • Daprodustat (GSK1278863)
  • Molidustat
  • Roxadustat (FG-4592)
  • Vadadustat (AKB-6548)
  • Xenon

1.3 GATA inhibitors, e.g.

  • K-11706

1.4 TGF-beta (TGF-β) signalling inhibitors, e.g.

1.5 Innate repair receptor agonists, e.g.

  • Asialo EPO
  • Carbamylated EPO (CEPO)

2. Peptide Hormones and their Releasing Factors

2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, in males, e.g.

2.2 Corticotrophins and their releasing factors, e.g.

2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to:

  • Growth Hormone fragments , e.g. AOD-9604 and hGH 176-191;
  • Growth Hormone Releasing Hormone (GHRH), e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin;
  • Growth Hormone Secretagogues (GHS), e.g. lenomorelin (ghrelin) and its mimetics, e.g. anamorelin, ipamorelin, macimorelin and tabimorelin;
  • GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin);

3. Growth Factors and Growth Factor Modulators, including, but not limited to:

  • Fibroblast Growth Factors (FGFs)
  • Hepatocyte Growth Factor (HGF)
  • Insulin-like Growth Factor-1 (IGF-1), and its analogues;
  • Mechano Growth Factors (MGFs)
  • Platelet-Derived Growth Factor (PDGF)
  • Vascular-Endothelial Growth Factor (VEGF)
  • Thymosin-β4 , and its derivatives e.g. TB-500;

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.